Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation

NCT05853575 is registered in ClinicalTrials.gov with Mirati Therapeutics Inc. as lead sponsor.

NCT NCT05853575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05853575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation
Lead sponsor
Mirati Therapeutics Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 1, 2024
Completion date
November 30, 2026
Enrollment
200 (estimated)
Sites
98

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, malignant neoplasm of lung, metastatic cancer